Exelixis, Inc. announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors and a second cohort of patients with advanced extra-pancreatic NET.
